- Email: [email protected]
5589336 Diagnostic method and kit for determining Kell blood group genotype
486
PATENT ABSTRACTS
A nucleic acid molecule which codes for a tumor rejection antigen precursor which is in turn processed to an antigen presented by HLA-B44 molecule is described. The antigen is also described. These materials are useful in diagnostic and therapeutic methodologies. The tumor rejection antigen precursor is not tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
amplification of KI/K2 nucleic acid sequences, and optionally employs differential cleavage of KI- and K2-specific nucleic acid sequences by a restriction enzyme. Also provided are nucleic acid oligomers useful as probes or primers for the method of the invention. Furthermore, diagnostic kits for the determination of Kell genotype are provided.
5589335 HYBRIDIZATION PROMOTION REAGENTS Kearney Kevin R; Collins Mark L; Eldredge John K; Morrissey David V Worcester, MA, UNITED STATES Assigned to Amoco Corporation Novel reagents are provided along with methods for their use in nucleic acid hybridization assays for detecting target nucleic acids in samples. The most preferred reagent is a mixture of guanidinium thiocyanate and tetramethylammonium:Trifluoracetate and possesses many properties for facilitating hybridization between target nucleic acid and nucleic acid probes capable of binding thereto and surprisingly results in the phenomenon of superstoichiometric labeling.
5589336 DIAGNOSTIC M E T H O D A N D KIT FOR D E T E R M I N I N G KELL BLOOD GROUP GENOTYPE Lee Soohee; Redman Colvin Cliffside Park, N J, UNITED STATES Assigned to New York Blood Center The invention provides a diagnostic method of determining Kell genotype by the identification of the molecular basis of a Kell polymorphism. Specifically, the invention provides a method for determining K1/K2 genotype with great accuracy, overcoming problems associated with traditional serological typing methods. The diagnostic method of the invention preferably employs
5589337 M E T H O D S AND DIAGNOSTIC KITS FOR DETERMINING TOXICITY UTILIZING BACTERIAL STRESS P R O M O T E R S FUSED TO REPORTER GENES Farr Spencer B Longmom, CO, UNITED STATES Assigned to The President and Fellows of Harvard College PCT No. PCT/US93/06537 Sec. 371 Date Jan. 6, 1995 Sec. 102(e) Date Jan. 6, 1995 PCT Filed Jul. 6, 1993 PCT Pub. No. WO94/01584 PCT Pub. Date Jan. 20, 1994. This invention provides methods and diagnostic kits for determining the toxicity of a compound. The methods and diagnostic kits of this invention employ a plurality of bacterial hosts, each of which harbors a DNA sequence encoding a different stress promoter fused to a gene which encodes an assayable product. Each of these stress promoters is induced by exposure to a different type of cellular stress. The stress promoters utilized in this invention, in toto, comprise those promoters which respond to redox stress, DNA stress, protein stress, energy stress and pH stress. The methods and diagnostic kits of this invention may be employed to characterize and quantify the toxicity of a compound, as well as to identify the cellular mechanism of its toxic action. Moreover, the methods of this invention yield information concerning the action of a compound on a subcellular level. This information may be utilized to design antitoxins to compounds found to be toxic and in active drug design.
PATENT ABSTRACTS
A nucleic acid molecule which codes for a tumor rejection antigen precursor which is in turn processed to an antigen presented by HLA-B44 molecule is described. The antigen is also described. These materials are useful in diagnostic and therapeutic methodologies. The tumor rejection antigen precursor is not tyrosinase, which has previously been identified as a tumor rejection antigen precursor processed to an antigen presented by HLA-B44.
amplification of KI/K2 nucleic acid sequences, and optionally employs differential cleavage of KI- and K2-specific nucleic acid sequences by a restriction enzyme. Also provided are nucleic acid oligomers useful as probes or primers for the method of the invention. Furthermore, diagnostic kits for the determination of Kell genotype are provided.
5589335 HYBRIDIZATION PROMOTION REAGENTS Kearney Kevin R; Collins Mark L; Eldredge John K; Morrissey David V Worcester, MA, UNITED STATES Assigned to Amoco Corporation Novel reagents are provided along with methods for their use in nucleic acid hybridization assays for detecting target nucleic acids in samples. The most preferred reagent is a mixture of guanidinium thiocyanate and tetramethylammonium:Trifluoracetate and possesses many properties for facilitating hybridization between target nucleic acid and nucleic acid probes capable of binding thereto and surprisingly results in the phenomenon of superstoichiometric labeling.
5589336 DIAGNOSTIC M E T H O D A N D KIT FOR D E T E R M I N I N G KELL BLOOD GROUP GENOTYPE Lee Soohee; Redman Colvin Cliffside Park, N J, UNITED STATES Assigned to New York Blood Center The invention provides a diagnostic method of determining Kell genotype by the identification of the molecular basis of a Kell polymorphism. Specifically, the invention provides a method for determining K1/K2 genotype with great accuracy, overcoming problems associated with traditional serological typing methods. The diagnostic method of the invention preferably employs
5589337 M E T H O D S AND DIAGNOSTIC KITS FOR DETERMINING TOXICITY UTILIZING BACTERIAL STRESS P R O M O T E R S FUSED TO REPORTER GENES Farr Spencer B Longmom, CO, UNITED STATES Assigned to The President and Fellows of Harvard College PCT No. PCT/US93/06537 Sec. 371 Date Jan. 6, 1995 Sec. 102(e) Date Jan. 6, 1995 PCT Filed Jul. 6, 1993 PCT Pub. No. WO94/01584 PCT Pub. Date Jan. 20, 1994. This invention provides methods and diagnostic kits for determining the toxicity of a compound. The methods and diagnostic kits of this invention employ a plurality of bacterial hosts, each of which harbors a DNA sequence encoding a different stress promoter fused to a gene which encodes an assayable product. Each of these stress promoters is induced by exposure to a different type of cellular stress. The stress promoters utilized in this invention, in toto, comprise those promoters which respond to redox stress, DNA stress, protein stress, energy stress and pH stress. The methods and diagnostic kits of this invention may be employed to characterize and quantify the toxicity of a compound, as well as to identify the cellular mechanism of its toxic action. Moreover, the methods of this invention yield information concerning the action of a compound on a subcellular level. This information may be utilized to design antitoxins to compounds found to be toxic and in active drug design.